Speakers
Poul Sørensen
Professor, Chief Scientific Officer & Co-Founder
Allero Therapeutics
Day Two
Thursday – January 28, 2021
9:30 am | Harnessing the Oral Mucosa for Antigen-Specific Immunotherapy of Immune Disorders
Rupert Sandbrink
Chief Executive Officer
Cellerys
Day Two
Thursday – January 28, 2021
3:00 pm | Establishing Immune Tolerance in Multiple Sclerosis Using Peptide-Coupled Red Blood Cells
Matthias von Herrath
Vice President & Senior Medical Officer, Global Chief Medical Officer
Novo Nordisk
Day One
Wednesday – January 27, 2021
2:00 pm | The Struggles with Immune Biomarkers and Pathologic Endotypes in Type 1 Diabetes
Charlotte Fribert
Chief Executive Officer
Toleranzia
Day Two
Thursday – January 28, 2021
9:00 am | Large Molecule Drug Development for the Treatment of Myasthenia Gravis
Evelien Schurgers
Associate Director Research
WORG Pharmaceuticals
Day Two
Thursday – January 28, 2021
2:30 pm | Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism
Jessica Grossman
Chief Executive Officer
IgGenix, Inc
Day One
Wednesday – January 27, 2021
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Antoon Van Oosterhout
Chief Scientific Officer, VP R&D
Imcyse
Day One
Wednesday – January 27, 2021
12:30 pm | Understanding the Mechanism of Action of Imotopes™ at Molecular and Cellular Level
James Moon
Co-Founder & Chief Scientific Officer; Professor of Pharmaceutical Sciences
EVOQ Therapeutics; University of Michigan
Day Two
Thursday – January 28, 2021
11:30 am | A Novel NanoDisc Platform for Systemic Targeting of Lymphoid Tissues and Induction of Antigen-Specific Immune Tolerance
Maria Wigren
Senior Scientist & R&D Team Leader
Idogen AB
Day Two
Thursday – January 28, 2021
10:00 am | Discussing a Tolerogenic Dendritic Cell Platform, Presenting the Antigen FVIII
Bryan Vander Lugt
Senior Scientist
Amgen
Day One
Wednesday – January 27, 2021
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
8:50 am | Chair’s Opening Remarks
Jessica Kenison
Senior Scientist
AnTolRx, Inc
Day Two
Thursday – January 28, 2021
12:30 pm | Antigen-Specific Tolerogenic Nanoparticles for the Treatment of Autoimmune Diseases
David Wraith
Founder & Chief Scientific Officer; Director, Institute of Immunology & Immunotherapy
Apitope; University of Birmingham
Day One
Wednesday – January 27, 2021
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Remi J. Creusot
Assistant Professor of Medical Sciences
Columbia University
Day One
Wednesday – January 27, 2021
11:30 am | Strategies for Epitope-Based Tolerance-Inducing Immunotherapy
Adam Elhofy
Director of Immunology
COUR Pharmaceuticals
Day One
Wednesday – January 27, 2021
3:00 pm | Antigen-Specific Tolerance to Multiple Epitopes in T1D
Ulf Hannelius
President & Chief Executive Officer
Diamyd Medical
Day One
Wednesday – January 27, 2021
4:00 pm | Precision Medicine and Antigens – The Case of HLA and GADSpecific Immunotherapy in Type 1 Diabetes
Klaus Ley
Professor/Division Head - Center for Autoimmunity & Inflammation
La Jolla Institute for Immunology
Day One
Wednesday – January 27, 2021
10:00 am | Inducing Tolerance to ApoB Epitopes to Curb Atherosclerosis
Wanjun Chen
Senior Investigator & Chief, Mucosal Immunology Section
NIDCR, NIH
Day One
Wednesday – January 27, 2021
9:30 am | Manipulation of TGF-β for Antigen-Specific Immunotherapy of Autoimmune Diseases
Stephen D. Miller
Judy Gugenheim Research Professor, Department of Microbiology- Immunology
Northwestern University Feinberg School of Medicine
Day One
Wednesday – January 27, 2021
2:30 pm | Requirement for Induced Tregs and Tr1 Cells or Regulation of Autoimmune Disease Using Antigen Encapsulating PLG Nanoparticles
Aaron Winkler
Research Fellow, Immune Tolerance Lead, Inflammation & Immunology
Pfizer, Inc.
Day Two
Thursday – January 28, 2021
8:50 am | Chair’s Opening Remarks
Klaus Martin
Chief Executive Officer
Topas Therapeutics
Day Two
Thursday – January 28, 2021
2:00 pm | To Be Announced
Agnete Fredriksen
Co-Founder, Chief Innovation & Strategy Officer
Vaccibody
Day One
Wednesday – January 27, 2021
12:00 pm | Targeting T-Cell Epitopes to Antigen-Presenting Cells to Induce Antigen-Specific Immune Tolerance
Rainer Henning
Chief Scientific Officer
WORG Pharmaceuticals
Day Two
Thursday – January 28, 2021